Equine grass sickness is associated with low antibody levels to Clostridium botulinum: a matched case-control study
Version of Record online: 5 JAN 2010
2004 EVJ Ltd
Equine Veterinary Journal
Volume 36, Issue 2, pages 123–129, March 2004
How to Cite
Mccarthy, H. E., French, N. P., Edwards, G. B., Poxton, I. R., Kelly, D. F., Payne-Johnson, C. E., Miller, K. and Proudman, C. J. (2004), Equine grass sickness is associated with low antibody levels to Clostridium botulinum: a matched case-control study. Equine Veterinary Journal, 36: 123–129. doi: 10.2746/0425164044868611
- Issue online: 5 JAN 2010
- Version of Record online: 5 JAN 2010
- Paper received for publication 24.12.02; Accepted 08.08.03
- equine grass sickness;
- Clostridium botulinum;
- case-control study
Reasons for performing study: Equine grass sickness is a high mortality disease which, despite many years of investigation, is of unknown aetiology. Recent findings indicating that the disease is associated with Clostridium botulinum require support from an epidemiological study that recognises and controls for potential confounders, e.g. age, time of year and premises.
Hypothesis: EGS is associated with low antibody levels to C. botulinum antigens.
Methods: A matched case-control study was conducted. Data were collected from 66 histologically confirmed cases of EGS and 132 premises-matched control horses. The probability of EGS in horses was modelled using conditional logistic regression.
Results: EGS was significantly associated (age-adjusted P<0.005) with low antibody levels to each of 3 clostridial antigens; C. botulinum type C and C. novyi type A surface antigens and a C. botulinum type C toxin complex toxoid. These serological risk factors for EGS remained highly significant when entered into multivariable models. This study also identified new horse-level risk factors for EGS; feeding hay or haylage was associated with a decreased risk of disease, change of feed type or quantity during the 14 days prior to disease was associated with increased risk, and the use of an ivermectin anthelmintic at both the ultimate and penultimate treatments was also associated with a significantly increased risk of EGS.
Conclusions: This study provides strong support for the role of C. botulinum in the aetiology of EGS and identifies managemental risk factors for the disease.
Potential relevance: Increasing anticlostridial antibody levels by vaccination and appropriate managemental interventions may decrease the risk of EGS occurring.;